Alternative Data for Ventyx Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 20 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 36 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,256 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 268 | Sign up | Sign up | Sign up |
About Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
| Price | $13.97 |
| Target Price | Sign up |
| Volume | 2,510,000 |
| Market Cap | $1B |
| Year Range | $2.02 - $14.03 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli LillyJanuary 7 - Slashdot.org |
|
 |
Eli Lilly Nears Deal to Buy Ventyx Biosciences for Over $1 BillionJanuary 6 - Yahoo |
|
Trending tickers: Micron, Sandisk Corporation, Ventyx Biosciences, BP and ReckittJanuary 6 - Yahoo |
 |
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars TodayJanuary 6 - Biztoc.com |
|
Ventyx Biosciences Launches On Rumored $1 Billion Eli Lilly TakeoverJanuary 6 - Yahoo |
|
Eli Lilly (LLY) Stock Is Up, What You Need To KnowJanuary 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -23M | -23M | -0.320 |
| Q2 '25 | 0 | 320,000 | -320,000 | -27M | -29M | -0.380 |
| Q1 '25 | 0 | 360,000 | -360,000 | -27M | -30M | -0.390 |
| Q4 '24 | 1.4M | 0 | 720,000 | -29M | -32M | -0.410 |
| Q3 '24 | 0 | 310,000 | -310,000 | -35M | -38M | -0.500 |
Insider Transactions View All
| Nuss John filed to sell 489,481 shares at $7.7. December 19 '25 |
| Mohan Raju filed to sell 2,372,863 shares at $7.7. December 19 '25 |
| Nuss John filed to sell 467,226 shares at $1.1. April 3 '25 |
| Nuss John filed to sell 464,582 shares at $2.4. December 30 '24 |
| Gujrathi Sheila filed to buy 130,000 shares at $2.3. December 26 '24 |
Similar companies
Read more about Ventyx Biosciences (VTYX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Ventyx Biosciences
The Market Cap of Ventyx Biosciences is $1B.
Currently, the price of one share of Ventyx Biosciences stock is $13.97.
The VTYX stock price chart above provides a comprehensive visual representation of Ventyx Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ventyx Biosciences shares. Our platform offers an up-to-date VTYX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Ventyx Biosciences (VTYX) does not offer dividends to its shareholders. Investors interested in Ventyx Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Ventyx Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
